NCT04682587 2025-01-03To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell CarcinomaPfizerCompleted481 enrolled 14 charts
NCT02791594 2024-11-08Imaging FDG Flare in MelanomaAbramson Cancer Center at Penn MedicineCompleted21 enrolled 10 charts